KOD · Kodiak Sciences Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $200.6M | $182.37M | $126.1M | $206.3M | $267.59M | $217.34M | $107.39M | $37.51M | $18.79M | $22.02M | $14.05M | |
| $45.82M | $52.02M | $60.75M | $71.02M | $73.79M | $49.71M | $28.62M | $11.68M | $7.58M | $3.5M | $3.1M | |
| $246.42M | $234.39M | $186.85M | $277.32M | $341.38M | $267.05M | $136.01M | $49.19M | $26.37M | $25.52M | $17.15M | |
| -$246.42M | -$234.39M | -$186.85M | -$277.32M | -$341.38M | -$267.05M | -$136.01M | -$49.19M | -$26.37M | -$25.52M | -$17.15M | |
| — | $0 | $0 | $13K | $18K | $47K | $25K | $8000 | $5.52M | $1.19M | $6000 | |
| $4.57M | $4.52M | $11.15M | $16.73M | $7.07M | $298K | $2.97M | $1.57M | $617K | $29K | — | |
| -$144K | -$96K | -$506K | $110K | $503K | -$190K | -$30K | $265K | -$4.69M | -$1.26M | $25K | |
| — | -$229.92M | -$176.19M | -$260.43M | -$333.79M | -$266.92M | -$133.08M | -$47.37M | -$41.44M | -$27.94M | -$17.13M | |
| — | $52K | $20K | $33K | $33K | $74K | $14K | — | — | — | — | |
| -$241.99M | -$229.97M | -$176.21M | -$260.49M | -$333.82M | -$266.99M | -$133.1M | -$47.37M | -$41.44M | -$27.94M | -$17.13M | |
| — | — | — | — | — | — | — | — | -$41.44M | -$27.94M | -$17.13M | |
| — | -$229.97M | -$176.21M | -$259.18M | -$335.13M | -$267.04M | -$133.05M | -$47.36M | -$41.44M | -$27.94M | — | |
| USD/shares | -$4.19 | -$4.32 | -$3.35 | -$4.97 | -$6.39 | -$5.16 | -$2.91 | — | — | — | — |
| USD/shares | -$4.19 | -$4.32 | -$3.35 | -$4.97 | -$6.39 | -$5.16 | -$2.91 | — | — | — | — |
| shares | — | 53.21M | 52.58M | 52.41M | 52.25M | 51.79M | 45.74M | 37.85M | 14.98M | 7.52M | 7.21M |
| shares | — | 53.21M | 52.58M | 52.41M | 52.25M | 51.79M | 45.74M | 37.85M | 14.98M | 7.52M | 7.21M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2018: $4000 in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 243 similar-size Biotechnology companies (of 514 listed).